(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/214492 A1

(51) International Patent Classification:
A61K 31/4196 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/GB2021/050999

(22) International Filing Date:
23 April 2021 (23.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2006072.9	24 April 2020 (24.04.2020)	GB
63/118,764	27 November 2020 (27.11.2020)	US
63/144,296	01 February 2021 (01.02.2021)	US
63/152,654	23 February 2021 (23.02.2021)	US

(71) Applicants: **BERGENBIO ASA** [NO/NO]; Jonas Lies vei 91, 5009 Bergen (NO). **THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, Texas 78701 (US).


(72) Inventors: **LORENS, James**; BerGenBio ASA, Jonas Lies Vei 91, 5009 Bergen (NO). **MICKLEM, David**; BerGenBio ASA, Jonas Lies Vei 91, 5009 Bergen (NO). **LI, Huiyu**; 5940 Forest Park Rd, Apt 4094, Dallas, TX 75235 (US). **LIU, Zhida**; 7 Xinhua Road, Xiaodian District, Taiyuan City, Shanxi Province, 030032 (CN). **MINNA, John**; 5323 Harry Hines Blvd., Dallas, TX 75390-9141 (US). **BREKKEN, Rolf**; 3822 Vancouver Cir., Dallas, TX 75229 (US).

(74) Agent: **ANDREWS, Robert**; Mewburn Ellis LLP, Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR

Figure 1



(57) Abstract: The invention relates to a method of selecting a subject for treatment with a combination of an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM), the method comprising: identifying subjects having an AXL-related disease characterised by the presence of cells having modified STK11 activity or expression; and, selecting thus identified subjects for treatment. The invention also relates to an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM) for use in the treatment of an AXL–related disease.

[Continued on next page]

WO 2021/214492 A1

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*